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ABSTRACT: Inherited thoracic aortopathies denote a group of congenital 
conditions that predispose to disease of the thoracic aorta. Aortic wall 
weakness and abnormal aortic hemodynamic profiles predispose these 
patients to dilatation of the thoracic aorta, which is generally silent 
but can precipitate aortic dissection or rupture with devastating and 
often fatal consequences. Current strategies to assess the future risk 
of aortic dissection or rupture are based primarily on monitoring aortic 
diameter. However, diameter alone is a poor predictor of risk, with many 
patients experiencing dissection or rupture below current intervention 
thresholds. Developing tools that improve the risk assessment of those 
with aortopathy is internationally regarded as a research priority. A 
robust understanding of the molecular pathways that lead to aortic wall 
weakness is required to identify biomarkers and therapeutic targets that 
could improve patient management. Here, we summarize the current 
understanding of the genetically determined mechanisms underlying 
inherited aortopathies and critically appraise the available blood 
biomarkers, imaging techniques, and therapeutic targets that have shown 
promise for improving the management of patients with these important 
and potentially fatal conditions.
The aorta is the largest artery in the body, beginning at the aortic valve of the heart and finishing at its bifurcation point in the pelvis. The aorta acts as a con-duit for blood by connecting the heart to the major arteries, ensuring blood 
flow to all the vital organs of the body. Being the most proximal artery to the heart, 
the thoracic aorta, the portion of the aorta contained within the chest, withstands 
the highest pressure and wall stresses through >30 million pressure cycles a year. 
The thoracic aortic wall must therefore function as a robust biomechanical struc-
ture, loading and unloading the cardiac volume efficiently and reliably throughout 
life. To achieve this, the molecular and biomechanical environment of the aortic 
wall is monitored and stabilized through a complex interplay between vascular wall 
cells and the extracellular matrix. Unfortunately, this robust homeostatic process 
can be disturbed through a variety of disease processes, collectively described as 
thoracic aortopathies, in which the thoracic aortic wall becomes weak and vulner-
able. Embryologically, the descending thoracic and abdominal aorta arises from the 
mesoderm, whereas the aortic root and ascending aorta are derived from the neu-
ral crest, leading to differences in gene expression and behavior of vascular smooth 
muscle cells in each region.1 Furthermore, the aortic wall composition, mechanisms 
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of aneurysm formation, and risk factors for their pro-
gression and complications are different in the 2 areas. 
Consequently, although there are distinct similarities, it 
is prudent to consider thoracic and abdominal aortic 
disease processes separately. Here, we focus on the dis-
ease processes of thoracic aortopathy.
THE NEED TO IMPROVE DETECTION 
AND MANAGEMENT OF INHERITED 
THORACIC AORTOPATHY
Inherited thoracic aortopathies denote conditions in 
which abnormalities lead to thoracic aortic wall weak-
ness or abnormal aortic hemodynamic profiles, predis-
posing patients to aortic dilatation, aneurysm forma-
tion, and acute aortic complications. Degradation of the 
components of the thoracic aortic wall can also occur 
as part of acquired processes, for example, associated 
with aging or high blood pressure, factors that poten-
tially compound genetically influenced thoracic aortic 
wall weakness. Patients with inherited aortopathy are 
at substantially increased risk of acute aortic complica-
tions, including aortic dissection or rupture, carrying 
with it major mortality risk. Because the outcomes from 
elective surgery are superior to those associated with 
emergency repair once dissection has occurred, current 
international guidelines advocate a focus on recognizing 
those at risk early, regular monitoring with imaging, and 
prophylactically replacing the diseased aortic segment 
once a threshold diameter is reached (Table 1).2–8 Even 
with these guidelines and robust monitoring, many pa-
tients with inherited thoracic aortopathy still experience 
aortic dissection or rupture while still below the thresh-
old diameter, whereas others may undergo surgery for 
thoracic aortic aneurysms that are unlikely to dissect or 
rupture.9,10 There is therefore universal agreement that 
better identification and risk stratification of thoracic 
aortopathy are urgently required. Indeed, a substantial 
body of research has been dedicated to exploring and 
developing novel solutions to this problem. This review 
summarizes the epidemiology and underlying pathologi-
cal processes associated with inherited aortopathy, out-
lines current management strategies, and examines the 
evidence supporting promising therapeutic targets and 
emerging biomarkers for these high-risk aortopathies.
ANATOMY, STRUCTURE, AND 
FUNCTION OF THE THORACIC AORTA
The thoracic aorta begins at the aortic valve, finishes as 
the aorta passes through the diaphragm, and is made 
up of 4 sections; the aortic root, which encompasses 
the coronary arteries that supply the heart; the tubu-
lar ascending aorta, which runs from the sinotubular 
junction to the origin of the brachiocephalic artery; the 
aortic arch, which contains the head and neck vessels 
and finishes just after the left subclavian artery; and the 
descending thoracic aorta, which ends at the level of 
the diaphragm (Figure 1). Inherited aortopathies can af-
fect any part of the thoracic aorta but most commonly 
affect the aortic root or ascending aorta.
Aortic dilatation in adults has classically referred to 
increased absolute aortic diameters based on refer-
ence thresholds, typically >40 mm, although a range 
of thresholds have been proposed and referenced in re-
search.11 However, concerns about increased risk of dis-
section occurring at lower gross diameters in smaller pa-
tients have led to wider use of aortic diameters adjusted 
for age, body surface area (aortic size index), or height 
(aortic height index), with aortic dilatation defined as an 
indexed aortic diameter z score >2.0 compared with ref-
erence populations.12,13 The terms “thoracic aortic aneu-
rysm” and “aortopathy” are often used interchangeably 
with aortic dilatation, although thoracic aortic aneurysm 
refers to an increase in diameter of >50%, a measure 
not commonly used accurately, whereas aortopathy is 
a generic description of a pathological process affecting 
the aorta, which can be a useful descriptor of a diseased 
aorta regardless of its diameter.
The aortic wall is histologically made up of 3 sections 
(Figure 1). The intima is the deepest, in direct contact 
with the lumen, and contains a lining of endothelial cells 
anchored by a basement membrane. The endothelial 
cells sense the hemodynamic and biochemical environ-
ment of the lumen and relay chemical signals to smooth 
muscle cells and fibroblast cells, allowing the aortic wall 
to adapt to both acute and chronic luminal changes.
The media is found superficially to the intima and 
is the most important contributor to biomechanical 
properties of the thoracic aortic wall. Specifically, the 
elastic fibers of the media, which are arranged in con-
centric layers and composed of extensively cross-linked 
tropoelastin, allow elastic fibers to be stretched and to 
recoil with minimal energy loss.14 Cross-linked elastin is 
formed primarily in the fetal and neonatal period and 
is insoluble with a half-life of 70 years, making it high-
ly durable.15 Newly formed elastin in adults is of low 
quality, rendering any damage to elastic fibers largely 
irreversible. There is also a demonstrable relationship 
between the number of intact elastin layers and the 
pressure required to propagate dissection or cause 
aortic rupture.16 Elastic fibers are anchored to vascular 
smooth muscle cells via focal adhesions, as well as be-
ing supported by a scaffold of extracellular molecules, 
including fibrillin, integrins, and collagen. Vascular 
smooth muscle cells and fibroblasts also maintain the 
extracellular matrix environment by producing tropo-
elastin, collagens, and microfibrils, along with proteins 
that promote medial healing and remodeling, for ex-
ample, matrix metalloproteinases (MMPs) and tissue 
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The outer section, the adventitia, is in communica-
tion with the nervous system and vasa vasorum, an 
external blood supply that also provides interaction 
with the immune system. The adventitia is composed 
primarily of fibroblasts that produce the fibrillar protein 
collagen. Unlike elastin, collagen has limited stretch or 
elasticity. However, it has a high resistance to biome-
chanical failure under peak stresses, meaning it plays an 
important role in protecting the aortic wall against rup-
ture.17 Although aortic dissection represents a tear of 
the medial elastic fibers and preservation of the adven-
titial collagen, rupture denotes biomechanical failure of 
both adventitial collagen and medial elastic fibers.
CATEGORIZING INHERITED THORACIC 
AORTOPATHIES
Inherited aortopathies are generally categorized into 
2 broad groups based on the clinical suspicion at pre-
sentation: syndromic or nonsyndromic aortopathy. Syn-
dromic heritable thoracic aortic disease (sHTAD) denotes 
a varied group of genetically mediated conditions that 
are associated with systemic features of disease, aortic 
dilatation, and acute aortic events. The major sHTADs, as 
published by the GenTAC Registry (National Registry of 
Genetically Triggered Thoracic Aortic Aneurysms) results, 
include Marfan syndrome, Turner syndrome, Loeys-Dietz 
syndrome, and vascular Ehlers-Danlos syndrome.18 A 
number of other genetically mediated syndromes such 
as Shprintzen-Goldberg syndrome (SKI mutations) are 
associated with aortic dilatation, although in these con-
ditions, progression to acute aortic events is exceptional 
or has not been reported (Table 2).
Non-sHTAD (nsHTAD) describes a familial form of 
aortopathy and dissections at a young age but without 
systemic features. In the past decade, studies explor-
ing the underlying genetic mechanisms of the nsHTAD 
groups have allowed a superior understanding of how 
gene mutations influence aortopathy risk.37 A recent in-
ternational consortium of experts in inherited thoracic 
aortic disease performed a validated semiquantitative 
analysis of the clinical and experimental data support-
ing a large number of genes associated with nonsyn-
dromic thoracic aortopathy, concluding that there was 
sufficient evidence that ACTA2, MYH11, MYLK, LOX, 
PRKG1, and FOXE3 confer a strong or definitive as-
sociation with nsHTAD.38 Similarly, patients who have 
Table 1. Summary of the Current Ascending Thoracic Aortic Aneurysm Diameter Thresholds for Considering Surgical Intervention
Condition Ascending Aortic/Aortic Root Threshold Diameter Guideline Reference
Marfan syndrome ≥45 mm with risk factors*  
≥50 mm
ESC (2014)2
Marfan syndrome ≥40 mm if considering pregnancy  
Consider at <50 mm if risk factors† 
 ≥50 mm
ACC/AHA (2010)4
Bicuspid aortic valve ≥45 mm if undergoing AVR  
≥50 mm with risk factors‡  
≥55 mm
ESC (2014)
Bicuspid aortic valve >45 mm if undergoing AVR for severe regurgitation/stenosis 
 >50 mm with risk factors†  
>55 mm
ACC/AHA (2014)5
Loeys-Dietz syndrome No specific recommendation ESC (2014)
Loeys-Dietz syndrome ≥42 mm on TEE ≥44 mm on CT/MRI ACC/AHA (2010)
Turner syndrome ASI ≥27.5 mm/m2 ESC (2014)
Turner syndrome 40–50 mm Cross-sectional aortic area/height >10 cm2/m ACC/AHA (2010)
Turner syndrome ASI ≥25 mm/m2 International Turner Syndrome Consensus 
Group (2017)3
nsHTAD No specific recommendation (although proposed 
thresholds of ≥42 mm or >3-mm growth rate for MYLK 
and >50 mm or >5-mm growth rate for MHY11 and 
ACTA2 have been proposed)6
ESC (2014) and ACC/AHA (2010)
nsHTAD 45–50 mm in ACTA2 VASCERN (2019)7
Ehlers-Danlos syndrome No specific recommendation (avoid if possible because of 
highly friable vascular tissue)
ESC (2014) ACC/AHA (2010)
ACC indicates American College of Cardiology; AHA, American Heart Association; ASI, aortic size index (aortic diameter/body surface area); 
AVR, aortic valve replacement; CT, computed tomography; ESC, European Society of Cardiology; MRI, magnetic resonance imaging; nsHTAD, 
nonsyndromic heritable thoracic aortic disease; TEE, transesophageal echocardiography; and VASCERN, European Reference Network on Rare 
Multisystemic Vascular Diseases.
*Risk factors include family history of dissection, size increase >3 mm/y, severe aortic regurgitation, or desire for pregnancy.
†Risk factors include family history of dissection at <50 mm, expanding aneurysm size of >5 mm/y, or significant aortic valve regurgitation.
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confirmed TGFBR1, TGFBR2, SMAD3, TGFB2, COL3A1, 
or FBN1 mutations but do not meet phenotypic di-
agnostic criteria for a specific syndrome are classified 
as having nsHTAD. This list of genes will continue to 
evolve as new research elucidates and corroborates 
causative gene mutations. To deliver optimal manage-
ment strategies for these patients, understanding the 
mechanisms by which gene mutations mediate disease 
and how these changes affect the risk of acute aortic 
events is crucial.
MARFAN SYNDROME AND FIBRILLIN
Marfan syndrome is a clinical diagnosis conferred to pa-
tients who meet the revised international criteria, with 
the majority having mutations in FBN1, which codes 
for a glycoprotein called fibrillin-1 (Figure 2).39 Without 
intervention, patients with Marfan syndrome have an 
average life expectancy of ≈40 years; 80% of mortal-
ity is related directly to aortic dilatation, dissection, and 
rupture. In the modern era of regular aortic monitor-
ing and prophylactic surgery, life expectancy has been 
much improved with reduced rates of acute aortic 
events (Table 2).40 Fibrillin-1 is the primary subunit of 
microfibrils, which are an important component of the 
aortic wall extracellular matrix. Fibrillin-1 plays a major 
role in the assembly and support of elastin by promot-
ing adhesion to vascular smooth muscle cells through 
interaction with lysyl oxidase (encoded by LOX) and 
fibronectin, as well as enhancing elasticity through its 
Figure 1. Anatomy and histology of the thoracic aorta.
Schematic representation of the thoracic aorta three-dimensional (3D) rendering from a contrast-enhanced magnetic resonance imaging (MRI) angiogram and 
both and tricuspid aortic valve from taken from MRI cine imaging (images captured on 3T Biograph mMR, Siemens, Erlangen, Germany; 3D rendering performed 
in Horos GNU Lesser General Public License, version 3) and a histological sample of the aortic wall stained with hematoxylin and eosin. The 3 layers of the aortic 
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microfibrillar structure (Figure 2).41 Changes in fibrilin-1 
lead to reduced elastic fiber genesis in early life and 
to reduced elastic fiber adhesion to vascular smooth 
muscle cells, both of which compromise the biome-
chanical integrity of the aortic wall. Fibrillin-1 also has 
a role in maintaining aortic wall homeostasis by bind-
ing to latent transforming growth hormone-β–binding 
proteins, which sequester transforming growth factor-β 
(TGFβ; Figure 2), a molecule implicated in the patho-
genesis of a number of inherited thoracic aortopathies.
LOEYS-DIETZ SYNDROME AND TGFΒ 
SIGNALING
Patients with Loeys-Dietz syndrome carry mutations 
that affect the signaling of TGFβ (TGFBR1, TGFBR2, 
TGFB2, TGFB3, SMAD2, and SMAD3), resulting in aor-
tic aneurysm, arterial tortuosity, hypertelorism, and bi-
fid uvula with a propensity toward arterial dissection 
or rupture at a young age.42 The systemic phenotype in 
Loeys-Dietz syndrome varies widely, with patients with 
more severe systemic phenotypes, particularly vertebral 
artery tortuosity, being more likely to experience aortic 
events.24 Initial descriptions of patients with TGFβR1 
or TGFβR2 mutations suggested a particularly low life 
expectancy of 26 years without intervention. However, 
a contemporary large international study demonstrates 
that the majority of patients are surviving past 70 years, 
albeit with an enduring high dissection prevalence (Ta-
ble 2).24 TGFβ is part of the cytokine superfamily and is 
enmeshed in many biological processes, including aor-
tic wall repair and homeostasis.43 TGFβ signaling fol-
lows 2 distinct and well-investigated pathways: small 
mothers against decapentaplegic (SMAD; canonical), 
or p38/extracellular signal-regulated kinase/c-Jun N-
terminal kinase (noncanonical), the latter of which is 
thought to be detrimental to thoracic aortic aneurysm 
formation, although the precise mechanisms are still 
controversial (Figure 2).44,45
VASCULAR EHLERS-DANLOS, 
OSTEOGENESIS IMPERFECTA, AND 
COLLAGEN
Pathological mutations in genes encoding type 3 (CO-
L3A1, vascular Ehlers-Danlos) and, to a lesser extent, 
type 1 collagen (COL1A1 and COL1A2, osteogenesis 
imperfecta) are associated with syndromic forms of 
Table 2. Epidemiological Data of the Major Inherited Thoracic Aortopathies Associated With Acute Aortic Events From Observational Studies 



















Degenerative aortopathy Unknown 1:10 0§ 1%§ 0.025%§19 No data‖ 6519
Syndromic inherited aortopathies
 Marfan syndrome FBN1 1:5000–1:15 00020 51%21 0.8%–12%18,21,22 7121 3721
 Loeys-Dietz syndrome TGFBR1/2, TGFB2, 
SMAD3
No data 20%23 16%24 3224 2623
 Turner syndrome 45X
?TIMP1, ?TIMP3
1:200025 35%26 1%–5%18,26–29 50–7727,28 31–3427,28
  Vascular Ehlers-Danlos 
syndrome
COL3A1 1:90 00030 No data 1.3%–5.8%18,30 No specific 
recommendation
3630







  Heritable thoracic aortic 
disease
FBN1, TGFBR1, TGFBR2, 
SMAD3, TGFB2, 
COL3A1, ACTA2, 
MYH11, MYLK, LOX, 
PRKG1, FOXE3¶
No data 9%–46%6,32 4%–43%6,22,33 46 had no aortic 
dilatation
436,22
 Bicuspid aortic valve ROBO4 GATA5, NOTCH1 1:50–1:100 35%34 0.1–0.2%34,35 7636 40–5636
*Dilation defined as root or ascending aortic diameter >40 mm all groups except for Turner syndrome, for which aortic size index (diameter/body surface area) 
>2.0 cm/m2 or Turner syndrome specific z score >2 was used.
†All results significantly influenced by adherence to surgical intervention guidelines.
‡Current surgical threshold as determined by American College of Cardiology/American Heart Association guidance.
§Prevalence among the general population not including bicuspid aortic valve or genetically determined aortopathy.
‖Many patients with dissection presenting as part of degenerative aortopathy have no previous aortic measurements recorded.
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aortopathy, and patients with such mutations are at 
increased risk of acute aortic events (Table  2).31 Pa-
tients with vascular Ehlers-Danlos have a reduced life 
expectancy with an average survival of 51 years, with 
the majority of mortality arising from vascular com-
plications. The arterial wall in vascular Ehlers-Danlos 
is particularly fragile with up to 6% experiencing 
dissection or rupture at an average age of 36 years, 
whereas individuals with osteogenesis imperfecta ex-
perience aortic dilatation relatively frequently (10%–
30%), but reports of dissection are very rare (Ta-
ble 2).18,30,31 Collagen is a fibrillar protein composed of 
a triple helix of α subunits that vary, depending on the 
type of collagen produced. The majority of collagen in 
Figure 2. Summary of the processes thought to be involved in thoracic aortopathy development.
The pathway affected as part of abnormal underlying processes in individual inherited thoracic aortopathies is highlighted. ECM indicates extracellular matrix; 
MMP, matrix metalloproteinase; nsHTAD, nonsyndromic heritable thoracic aneurysm and dissection; TGFβ, transforming growth factor-β; TIMP, tissue inhibitor of 
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the thoracic aorta is type 3 or 1, both of which con-
fer robust ultimate strength, preventing rupture (Fig-
ure 2). Although the mechanism by which types 3 and 
1 collagen mutations cause aortic wall vulnerability is 
intuitive, the role of collagen remodeling in other in-
herited thoracic aortopathies is unclear, with contrast-
ing reports of increased and decreased concentrations 
in response to aneurysm formation.
TURNER SYNDROME AND TIMPS
Turner syndrome is the complete or partial loss of the 
second X chromosome, affecting ≈1 in 2000 wom-
en,25 although mosaicism can also occur and can af-
fect men. It is associated with short stature, abnormal 
facies, and hypogonadism, with congenital heart dis-
ease affecting 25% to 50%, typically bicuspid aortic 
valve or coarctation of the aorta. There is a growing 
recognition that patients with Turner syndrome are at 
risk of thoracic aortopathy,27 with >35% reported as 
dilated and up to 5% experiencing dissection or rup-
ture (Table 2).18 Similar to other inherited thoracic aor-
topathies, the precise mechanism of disease in Turner 
syndrome remains elusive, although recent genetic 
studies have implicated TIMP1 and TIMP3.46 Haploin-
sufficiency of TIMP1 increased the risk of aortopathy 
10-fold, and concomitant TIMP3 mutation augment-
ed that risk to 18-fold.26 Given the evolving role that 
TIMPs have in aortic remodeling and aneurysm forma-
tion, TIMP1 and TIMP3 may be important targets for 




nsHTAD represents a relatively heterogeneous cohort of 
patients with a family history of aortic dissection at a 
young age with no clear syndromic features suggestive 
of a connective tissue disease. Nonsyndromic aortopa-
thy is increasingly recognized as an important clinical 
entity, seen in up to 89% of aortopathy cohorts.47 The 
underlying genetic causes of nsHTAD include mutations 
in genes encoding members of TGFβ signaling path-
way (TGFBR1, TGFBR2, TGFB2, SMAD3); the structure 
and integrity of the aortic wall extracellular matrix, in-
cluding FBN1 (described earlier); COL3A1 and lysyl oxi-
dase (LOX); or those affecting the function of smooth 
muscle cells, including actin (ACTA2), myosin (MYH11), 
myosin light chain kinase (MYLK), and protein kinase 
cGMP-dependent 1 (PRKG1). Taken together, caus-
ative mutations can be found in only ≈20% of nsHTAD 
cases, leaving many without a genetic diagnosis.32 In 
probands with a confirmed mutation, many have mu-
tations in FBN1 without meeting revised Ghent criteria 
to diagnose Marfan syndrome.47 Furthermore, up to 
35% have mutations in SMAD3 and 14% have ACTA2 
mutations, whereas pathological mutations in MYH11, 
MYLK, PRKG1, LOX, and other less well-depicted genes 
are limited to a smaller number of families.33,48,49 In a 
cohort of patients experiencing acute aortic events with 
confirmed pathological mutations, the average age at 
the time of the event was 41 years, with only 54% hav-
ing aortic root aneurysms (Table 2).32 Those with patho-
logical mutations are more likely to experience aortic 
intervention or dissection at a young age, particularly 
those <50 years of age, whereas those >60 years of age 
are much less likely to carry pathological mutations.33,47 
In patients with nsHTAD with a pathogenic mutation, 
many mutations cause disease by affecting the function 
of vascular smooth muscle cells.33,47 Vascular smooth 
muscle cells are the primary cell of the medial layer, 
providing contractile stress (tone) and anchoring the 
elastic fibers of the extracellular matrix, which confers 
overall stability. The intracellular structure of vascular 
smooth muscle cells and tone generation are governed 
by smooth muscle cell–specific α-actin and myosin, 
the function of which can be disrupted in the vascular 
smooth muscle cell mutations, leading to increased cell 
death, decreased aortic wall tone, and reduced extra-
cellular matrix stability (Figure 2).
BICUSPID AORTIC VALVE 
AORTOPATHY, ABNORMAL AORTIC 
DEVELOPMENT, AND ABNORMAL 
FLOW
Bicuspid aortic valve affects 0.5% to 2% of the popula-
tion and denotes an aortic valve composed of 2, rather 
than 3, aortic leaflets (Figure 1).50 Patients with bicuspid 
aortic valve are at increased risk of aortic stenosis and 
regurgitation and are significantly more likely to experi-
ence ascending aortic dilatation and acute aortic events 
(Table  2). The mechanisms that predispose patients 
with bicuspid aortic valve to aortopathy are still emerg-
ing, with evidence supporting both biomechanical and 
genetic causes. Multiple studies have demonstrated the 
important influence that abnormal thoracic aortic flow 
patterns have on underlying aortic wall TGFββ pathway 
signaling, elastin breakdown, dilatation location, and 
the risk of aortic events.51,52
There are sex and racial differences in the prevalence 
of bicuspid aortic valve, with men and white individu-
als the most likely to be affected.53 Furthermore, there 
is clustering of affected individuals within families. 
Taken together, these strongly suggest the presence of 
an inherited disease process. Yet, similar to nsHTAD, in 
the majority of cases, no definite genetic cause can be 
found.54 In those patients with mutations known to af-
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TGFβ βpathway mutations, there is an increased preva-
lence of bicuspid aortic valve, suggesting an inherent link 
between bicuspid aortic valve formation and thoracic 
aortopathy in these groups.55 Furthermore, there is a 
growing number of reports describing specific mutations 
in patients with bicuspid aortic valve and aortopathy but 
without the systemic features of connective tissue dis-
ease, for example, ROBO4 and NOTCH1, which affect 
endothelial permeability and endocardial/endothelial 
differentiation, respectively, although the link between 
NOTCH1 and aortic events is not well described.56,57 
Overall, although bicuspid aortic valve is an independent 
risk factor for developing a progressive aortopathy, it is 
clear that the risks are compounded by a spectrum of 
genetic variants that affect how the thoracic aortic wall 
develops and remodels. In clinical practice, the ambiguity 
surrounding the genetic influence on acute aortic event 
risk can make deciding when to offer familial aortic 
screening and genetic evaluation challenging.
CLINICAL EVALUATION AND GENETIC 
TESTING IN SUSPECTED INHERITED 
AORTOPATHY
When patients and their families are being investigated 
for suspected inherited thoracic aortopathy, important 
consideration will be given to whether genetic testing 
is indicated and how to counsel patients about the po-
tential implications. Here again, it is useful to split into 
syndromic and nonsyndromic categories. In a patient 
presenting with suspected sHTAD, imaging and ge-
netic investigations vary significantly according to the 
proband phenotype (summarized in Table  3). Familial 
testing in relatives will be guided by a genetics special-
ist and will be focused on those family members with 
phenotypic features suggestive of the condition.
Managing patients presenting as the proband for 
nsHTAD can be challenging, with a degree of uncer-
tainty often surrounding diagnosis, prognosis, and how 
to investigate family members. First, careful elucidation 
of any family history of acute aortic events, including 
sudden unexplained death at a young age, is important 
in establishing a clear heritable aortopathy. Echocardio-
graphic screening of the aorta in first-degree relatives 
can be a useful and affordable tool for establishing the 
prevalence of aortic dilatation within the family, both 
solidifying a diagnosis of an inherited aortopathy and 
identifying at-risk family members who will require 
more regular aortic surveillance (Figure  3). Second, 
because nsHTAD with aortic dilatation or dissection in 
patients <50 years of age has a stronger likelihood of 
identifiable genetic mutations, offering genetic testing 
in these patients is reasonable even in the absence of 
a clear family history (Figure 3).32,47 When a heritable 
thoracic aortopathy is suspected, genetic testing should 
be considered carefully and discussed with the family, 
usually by a geneticist specialist.
Genetic screening in nsHTAD has developed over the 
past decade and can be beneficial when applied in the 
right context by providing more personalized selection 
for aortic surveillance and the timing of prophylactic 
aortic surgery and conveying a better understanding of 
the risks of pregnancy and to future offspring. In the 
clinical setting, this genetic testing is best performed 
when positive results are actionable by adding mean-
ingful prognostic information affecting the patient’s 
medical care and influencing important clinical deci-
sions, for example, the timing of prophylactic aortic 
replacement surgery. Families should be aware that 
a clear genetic cause can be found in only ≈20% of 
cases, which may lead to a degree of uncertainty.33 In 
these cases, a robust mechanism for monitoring fam-
ily members, whether apparently affected or not, will 
be required because aortopathy may not develop until 
later in life (Figure  3).58 The majority of commercially 
available gene panels across the United States and Eu-
rope also include targeted sequencing of genes with 
an association with thoracic aortopathy that is less well 
established (Figure 3). Although there is a role for ex-
panded genetic testing, particularly in the context of 
gene discovery research, prospective counseling on the 
consequences of uncertain results and follow-up aor-
tic monitoring will be crucial when supporting families 
in this scenario. Improved understanding of the gene-
disease aortic risk association and novel gene discovery 
are going to be vital to improving the care received by 
these families with inherited aortopathies. To move to-
ward the eventual goal of personalized gene-adapted 
management, longitudinal international collaboration 
with the pooling of affected patients will be essential to 
overcoming the lack of power consequent to the rarity 
of gene-positive disease. Until then, treatment, man-
agement, and counseling of patients with a confirmed 
inherited aortic disease are based on reducing the risk 
of acute aortic events through an understanding of bio-
mechanical and biological principles.
BIOMECHANICAL PRINCIPLES OF 
AORTOPATHY RISK
Acute aortic events represent the biomechanical failure 
of the layers of the aortic wall and occur when the wall 
stress exceeds the ultimate rupture strength. Increased 
aortic wall circumferential stress is understood to be 
related to an increase in blood pressure and aortic di-
ameter or a decrease in aortic wall thickness through 
the Law of Laplace. Expansion of aortic diameter with 
sustained blood pressure, as with aortic dilatation, in-
creases wall stress and subsequently the risk of acute 
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increase in aortic event rate seen in ascending aortic 
aneurysms >60 mm. Similarly, increased blood pressure 
caused by raised systemic vascular resistance—for ex-
ample, coarctation, obesity, or essential hypertension—
raises wall stress and consequently the risk of acute 
aortic events.35 Likewise, pregnancy is associated with 
increased cardiac output and hormonal changes that, 
in the context of aortopathy, can lead to an irreversible 
increase in aortic root diameter and a higher likelihood 
of acute aortic events.59 This risk is reflected in current 
international counseling guidance that categorizes all 
inherited thoracic aortic diseases as at least modified 
World Health Organization risk group II (small increase 
risk of maternal mortality or moderate increased risk of 
morbidity) with a reasonable proportion in the highest 
risk category IV (extremely high risk of maternal mor-
tality or severe morbidity), depending on the condition 
and degree of prepregnancy aortic dilatation (Table 4).60 
Prepregnancy counseling is therefore crucial for women 
of child-bearing age with aortopathy.
Under normal circumstances, when blood pressure 
is sustainably raised, the aortic wall remodels and in-
creases in thickness, thereby keeping circumferential 
stress relatively constant. However, there is emerging 
evidence that remodeling that results in reduced com-
pliance of the aortic wall is a worrying feature of aor-
topathy.
AORTIC STIFFNESS
Aortic stiffness is a marker of how easily the aortic wall 
distends with applied pressure. With noninvasive two-
dimensional aortic imaging (computed tomography, 
magnetic resonance imaging [MRI], or ultrasound), aor-
tic compliance can be assessed by the use of strain, the 
increase in the aortic wall length as a proportion of the 
baseline length. Strain can be measured in the circum-
ferential and longitudinal directions, with distensibil-
ity representing circumferential strain divided by pulse 
pressure.62 Alternatively, aortic stiffness can be inferred 
from how quickly the pulse wave propagates through 
Table 3. Summary of Diagnostic Criteria, Imaging Assessment, and Targeted Genetic Testing for Syndromic Inherited Aortopathies
Suspected Syndrome Clinical Features and Diagnosis Imaging Assessment Targeted Genetic Testing
Marfan syndrome With family history:
Ectopia lentis, systemic score ≥7, aortic root 
dilatation
With no family history:
Aortic root dilatation AND ectopia lentis, 
aortic root dilatation AND systemic score ≥7, 
aortic root dilatation AND FBN1 mutation, 
ectopia lentis AND FBN1 mutation
Baseline MRI (or CT/TEE/TTE if unable) of whole 
thoracic aorta
Follow-up imaging at 6 mo and then annually 
to assess growth rate with same modality
FBN1,* TGFBR1, TGFBR2, 
BGN
Loeys-Dietz syndrome Arterial tortuosity, aortic dilatation and 
dissection, bifid uvula, cleft palate, 
craniosynostosis, systemic features similar to 
Marfan syndrome
Consider baseline MRI of arterial vessels from 
cerebrovascular to pelvis 
Follow-up imaging at 6 mo and then annually 






Translucent skin, abnormal facies, easy 
bruising, aortic dilatation, arterial fragility
Baseline CT/MRI from cerebrovascular vessels 
to pelvis
Follow-up dependent on initial findings TTE 
3–5 times yearly for aortic assessment is 
reasonable.
COL3A1*
Turner syndrome Missing or partially missing X chromosome 
diagnosed via karyotyping; short stature, 
ovarian failure, webbed neck, broad chest, 
cardiac and renal defects
Baseline TTE at diagnosis, MRI/CT when 
tolerated
Follow-up every 6 mo–5 y depending on z 
score and risk factors




Craniosynostosis, learning difficulty, abnormal 
facies, hypotonia, Marfan-like skeletal 
abnormalities, aortic dilatation
Baseline TTE of aortic root and ascending aorta
Consider MRI/CT of whole aorta
Follow-up 5-y TTE of aortic root and ascending 
aorta
SKI*
Osteogenesis imperfecta Multiple fractures, poorly developed 
dentition, hearing loss, blue sclera, aortic 
dilatation
Baseline echocardiogram for aortic diameters 
and valve function
Consider MRI/CT of whole aorta
Consider follow-up TTE every 3–5 y
COL1A1,* COL1A2*
Arterial tortuosity syndrome Severe arteriopathy affecting pulmonary and 
aortic vessels with sequelae at a young age, 
hyperextendable joints, abnormal facies, 
congenital contractures, abdominal hernias
Baseline CT angiography is commonly used in 
elucidating arterial anatomy
Follow-up depends on the arterial anatomy
SLC2A10*
CT indicates computed tomography; MRI, magnetic resonance imaging; TEE, transesophageal echocardiography; and TTE, transthoracic echocardiography.
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the aorta, known as pulse-wave velocity, which is mea-
sured with applanation tomography or extrapolated 
from four-dimensional flow sequences on MRI.
Aortopathy in Marfan syndrome, Loeys-Dietz syn-
drome, Turner syndrome, and nsHTAD is associated with 
increased aortic stiffness.63,64 Ex vivo biomechanical test-
ing of dilated aortas demonstrates that increased stiffness 
appears to be attributable to higher collagen and lower 
elastin content, making aortic stiffness a proxy marker of 
wall remodeling, which may be apparent well before aor-
tic diameters begin to increase.14 Consistently, the aortic 
stiffness increases with age, and a steep rise in stiffness 
is seen after 55 years of age, coinciding with the natural 
decreases in elastin. There is also a strong relationship be-
tween increasing diameter and increasing aortic stiffness. 
In Marfan syndrome, aortic stiffness is increased in those 
with either dilated or nondilated aortas. More impor-
tant, reduced longitudinal aortic strain is associated with 
increased aortic event rates in Marfan syndrome after 
adjustment for aortic diameter.62 Larger studies are re-
quired to corroborate the role of aortic stiffness in identi-
fying high-risk aortopathy after adjustment for dilatation 
in connective tissue disorders and bicuspid aortic valve.
In patients whose aorta is inherently weak or remod-
els abnormally, as with inherited aortopathies, increases 
in blood pressure, systemic vascular resistance, and aor-
tic stiffness are detrimental and should be addressed. 
In the past decade, significant research effort has fo-
cused on improving our understanding of how medical 
therapies can affect outcomes through their influence 
on biomechanical and biological properties.
MEDICAL TREATMENT OF THORACIC 
AORTOPATHIES
Conventional therapies have focused on reducing 
aortic wall stress by lowering blood pressure and 
Figure 3. Summary of the management for imaging, family screening, and counseling management for inherited thoracic aortopathies.
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systemic vascular resistance. The 2017 American Col-
lege of Cardiology/American Heart Association guide-
line for the treatment of hypertension recommends 
β-blockers as first-line treatment in all thoracic aneu-
rysm disease.65 The European Society of Cardiology/
European Society of Hypertension 2018 guideline on 
the management of hypertension in aortic diseases 
recommends strict blood pressure control to <130/80 
mm Hg.61 The evidence for a benefit for presump-
tive β-blocker therapy stems from a reduced rate of 
aortic dilatation associated with a reduction in blood 
pressure and acute aortic events in nonhypertensive 
patients with Marfan syndrome treated with propran-
olol compared with control subjects.66 Angiotensin 
receptor blockers, which target the AT1 receptor with 
a consequent reduction in TGFβ signaling, have also 
been investigated as a potential therapeutic target, 
given the promising results in animal models. Large 
randomized controlled trials conducted so far have 
not found an effect of angiotensin receptor blockers 
on clinical outcome compared with the protection 
provided by β-blocker therapy.67–69 There is, howev-
er, some recent promise for the ability of irbesartan 
to reduce aortic growth rate when added to current 
treatment.70 Although currently there is not enough 
evidence to recommend angiotensin receptor blocker 
therapy over β-blocker therapy, its use is reasonable 
when β-blocker therapy is poorly tolerated. Further 
elucidation of the mechanisms governing TGFβ activ-
ity in Marfan syndrome is required.
Although there is some evidence base for β-blocker 
or angiotensin receptor blocker therapy in Marfan syn-
drome, calcium channel blockers appear to be detri-
mental. Both murine models and a case-controlled 
analysis of humans with Marfan syndrome demonstrat-
ed an increased risk of dissection/rupture for treatment 
with channel blockers.71 Similarly, fluoroquinolone use 
appears to be linked to aortic aneurysm formation and 
dissection in the general population, possibly through 
an imbalance of TIMPs and MMPs (Figure  2) and re-
duced collagen.72,73 Although medical therapy in Mar-
fan syndrome is relatively well studied, the evidence for 
presumptive blood pressure–lowering therapy in other 
inherited aortopathies is scarce.
In vascular Ehlers-Danlos syndrome, treatment with 
celiprolol (a selective B1 blocker) was associated with 
a reduced event rate, although there was a small in-
crease in brachial blood pressure, suggesting that 
blood pressure was not the mediator of aortic risk in 
these patients.74 The guidance on the medical man-
agement for other inherited thoracic aortopathy is ex-
trapolated from studies on Marfan syndrome. Given 
the diverse mechanisms of aortic wall vulnerability in 
inherited aortopathies (Figure 2), studies that examine 
the role of both established and novel medical thera-
pies in specific inherited aortopathies, for example, the 
role of angiotensin receptor blocker therapy in Loeys-
Dietz syndrome, are required to provide improved and 
targeted therapy.
Table 4. Summary of Current Treatment Guidance for Inherited Thoracic Aortic Diseases
Condition Medical Therapy Counseling for Pregnancy60
Marfan syndrome Aim to keep blood pressure under 130/80 mm Hg61
Consider prophylactic treatment with β-blockers or 
angiotensin receptor blocker
Avoid calcium channel blockers and fluoroquinolone 
use
No dilatation, mWHO class II–III Intermediate risk of 
maternal mortality (maternal cardiac event rate, 10%–
19%)
40–45 mm, mWHO class III Significantly increased risk of 
maternal mortality; requires expert counseling (maternal 
cardiac event rate, 19%–27%)
>45 mm, mWHO class IV Extremely high risk of maternal 
mortality; termination should be sensitively discussed if 
pregnancy occurs (maternal cardiac event rate, 40%–100%)
Loeys-Dietz syndrome As per Marfan syndrome As per Marfan syndrome
Turner syndrome Aim to keep blood pressure <140 mm Hg if aortic 
root >30 mm and <120 mm Hg if concurrent 
bicuspid aortic valve
If aortic size index >2.3 cm/m2, treat with β-blocker, 
angiotensin receptor blocker, or both3
No dilatation, mWHO class II 
Small increased risk of maternal mortality or moderate 
increase in morbidity (maternal cardiac event rate, 5.7%–
10.5%)
Aortic size index, 2.0–2.5 cm/m2, mWHO class III
Aortic size index >2.5 cm/m2, mWHO class IV
Vascular Ehlers-Danlos syndrome Prophylactic treatment with celiprolol is reasonable All patients, mWHO class IV
nsHTAD As per Marfan syndrome As per Marfan Syndrome
Bicuspid aortic valve Aim to keep blood pressure <140/90 mm Hg without 
aortic dilatation or 130/80 mm Hg with aortic 
dilatation
Avoid calcium channel blockers and fluoroquinolone 
use
<45 mm, mWHO class II–III
45–50 mm, mWHO class III
>50 mm, mWHO class IV
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Given that between 30% and 80% of acute aortic 
events in those with inherited aortopathy occur under 
surgical thresholds (Table 2), novel methods of identify-
ing patients with thoracic aortic disease at high risk of 
dissection or rupture are urgently required.
BLOOD AND TISSUE MARKERS OF 
INHERITED THORACIC AORTOPATHY
Although understanding of the processes that govern 
the different inherited thoracic aortopathies has pro-
gressed, translating these findings into therapeutic tar-
gets or robust markers of thoracic aortic disease sever-
ity is still in the early stages. Blood markers are easy 
to obtain and relatively cheap, making them an attrac-
tive option if a reliable, sensitive, and specific test can 
be found. Research efforts to uncover such a suitable 
blood marker have focused primarily on mediators and 
markers of aortic wall destruction. Here, the pathways 
targeted as part of translational work performed thus 
far are summarized, but a detailed overview of each 
family of molecules is beyond the scope of this review.
Plasma TGFβ
As outlined, murine models of both Marfan syndrome 
and Loeys-Dietz syndrome have implicated TGFβ sig-
naling, particularly the noncanonical pathway, as be-
ing detrimental (Figure 2). Blood measurement of TGFβ 
is an attractive biomarker both for linking to disease 
progression and as a research tool in measuring effects 
of TGFβ-modifying treatments (eg, TGFβ response to 
angiotensin receptor blocker therapy). Progress to-
ward translation has been hampered by difficulties in 
reliably measuring active TGFβ1 in the blood. Platelets 
are TGFβ1 rich, and degranulation, as occurs in serum 
preparation and when exposed to high shear stress as 
part of sampling, can contribute to 90% of TGFβ1 lev-
els and therefore mask any changes caused by patho-
logical processes.75 Optimal blood-taking methodology 
that reduces the amount of platelet degranulation has 
been well described,76 with many studies not report-
ing venesection techniques or measuring concomitant 
platelet activation. When concomitant platelet activ-
ity is assessed, no difference can be found in plasma 
TGFβ1 concentrations between patients with Marfan 
syndrome with dilated aortic roots or previous surgery 
and control subjects.77 Given the evidence for its role in 
the progression of aortopathy, active TGFβ1 could be 
a useful marker of disease progression and a guide to 
effective medical treatment. However, more research is 
required to ensure reliability (adjusting for platelet acti-
vation) and international consistency. Furthermore, be-
cause TGFβ1 is abundant throughout the body, wheth-
er plasma concentrations specifically reflect aortic wall 
activity and predict disease progression remains to be 
validated.
Matrix Metalloproteinases
MMPs are a family of 23 separate molecules that share 
the characteristic feature of a zinc-binding catalytic 
area and are secreted by vascular smooth muscle cells, 
fibroblasts, and immune cells in response to chemical or 
biomechanical stress. The primary role of these MMPs 
is to cleave and digest extracellular proteins such as 
elastin, collagen, and integrins as part of aortic wall re-
pair, remodeling, and homeostasis. Under pathological 
conditions, the unchecked activity of specific MMPs can 
be detrimental to the cardiovascular system by causing 
excess destruction of vascular wall components. Murine 
studies have specifically implicated MMP-2 and MMP-9 
in thoracic aortic aneurysm formation, and they are the 
most promising targets for translation as markers and 
potential modulators of disease.78,79
Efforts have been made to use MMP-2 and MMP-9 
as prognostic biomarkers for thoracic aortic disease se-
verity. Human induced pluripotent stem cell line study of 
patients with Marfan syndrome demonstrates increased 
MMP-9 levels compared with reference cell lines.80 As 
with TGFβ1, translation of MMPs into reliable biomark-
ers of aortic wall remodeling is attractive. However, blood 
MMP-9 and MMP-2 concentrations are sensitive to caf-
feine and the collection method (citrate deemed most 
stable) and require quick processing (within 2 hours) to 
prevent artifactual changes in quantification.81,82 Appro-
priately measured plasma MMP-2 concentrations have 
been linked to increased aortic diameter and repeatably 
linked to increased aortic stiffness, although no studies 
to date have made links to outcomes.83,84 Given their as-
sociation with abnormal aortic function and the mecha-
nism of action, MMPs have been a target for translation 
of medical therapy. Doxycycline, a generalized inhibitor 
of MMPs, can prevent aneurysm formation and pre-
serve elastic fiber integrity and aortic biomechanics in 
animal models.85 However, when translated to human 
abdominal aortic aneurysms, 100 mg doxycycline over 
18 months resulted in a small but significant increase, 
rather than decrease, in aortic growth rate compared 
with placebo.86 Although MMPs appear to play a role 
in aortic wall pathology, their precise role remains to be 
determined. Progress may be made by improving our 
understanding of how MMPs are moderated through 
their naturally occurring inhibitors.
Tissue Inhibitors of MMP
TIMPs are a family of 4 naturally occurring and non-
specific MMP inhibitors found in a wide variety of bio-
logical systems, including the vasculature. They func-
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and deactivating pro–MMP-2 and -9, working in con-
cert to promote vascular homeostasis without excess 
destruction. Under pathological circumstances, MMP 
activity unchecked by TIMP is thought to promote ab-
normal remodeling.
Turner syndrome is an interesting inherited thorac-
ic aortopathy with a high incidence of bicuspid aortic 
valve that can be used to study TIMP1 as a mediator 
of thoracic aortopathy. The gene is located on the X 
chromosome, 1 copy of which is lost in many cases of 
Turner syndrome.26 Moreover, because bicuspid aortic 
valve disease is male predominant, some have specu-
lated that having 2 sets of X chromosomes is in some 
way protective against bicuspid aortic valve and aortop-
athy. Although TIMP1 may be implicated in inherited 
aortopathic disease, there is little evidence that plasma 
TIMP1 concentrations reflect gene copy number or mir-
ror aortic pathological processes.46,87 Some researchers 
have instead focused on the ratio of MMPs to TIMPs, 
giving a picture of an overall balance between remod-
eling and destruction and finding increased ratios in 
those with bicuspid aortic valve, although these find-
ings require further validation.88
Overall, the roles of TIMP1 as a mediator of remodel-
ing make an attractive target for biomarker translation, 
particularly when coupled with MMP-2 and MMP-9 to 
give a representation of remodeling activity balance. 
However, as with many biomarkers, both MMPs and 
TIMPs are involved in many biological processes; there-
fore, blood concentrations may not be specific enough 
to represent thoracic aortic remodeling.
Desmosine
A promising development in biomarker research for 
thoracic aortopathies lies in plasma desmosine, a 
rare molecule that is necessary for cross-linking tro-
poelastin. Desmosine appears to increase with age 
and is elevated in patients with chronic obstructive 
pulmonary disease, reflecting elastin breakdown.89 
Desmosine has very few other functions in humans, 
potentially making it a specific marker of aortic wall 
elastin breakdown.90 In abdominal aortic aneurysms, 
increasing plasma desmosine concentrations were 
associated with aortic diameter and an increasing 
likelihood of aortic events, after adjustment for di-
ameter.91 Although the breakdown of elastin is not 
specific to a single inherited aortopathy, it represents 
an end point thought to correlate with biomechani-
cal weakness and a tendency toward failure. Studies 
exploring the utility of plasma desmosine concentra-
tions to predict dissection or rupture in thoracic aor-
topathy would be highly valuable.
Although a significant amount of research has fo-
cused on novel blood biomarkers, the evidence support-
ing their role as a complementary marker of aortopathy 
risk is relatively weak, with most targets being involved 
in many processes throughout the body. Therefore, 
blood concentrations are unlikely to reflect changes 
at the aortic wall level. In this regard, molecular imag-
ing techniques, which allow the direct visualization of 
biological processes at specific anatomic locations, may 
prove beneficial.
MOLECULAR MARKERS OF 
AORTOPATHY
Advanced imaging techniques with specific tracers have 
the potential to localize and quantify (patho)biological 
processes occurring within the body. Molecular imaging 
with a radioactive molecule or a targeted smart con-
trast agent can be used to provide combined functional 
and structural imaging with a range of imaging tech-
niques such as positron emission tomography, MRI, or 
computed tomography. The anatomic visualization of 
molecular activity allows organ-specific assessment of 
these processes, improving accuracy and specificity.
Elastin-Specific MRI Contrast Agent
Complementing the blood biomarker desmosine, an 
elastin-specific MRI contrast agent (ESMA) is now being 
investigated as a way of highlighting the aortic wall, 
with reduced uptake associated with decreased elastin 
content and aortic wall disease.92 In the murine model 
of Marfan syndrome, in vivo ESMA MRI quantification 
demonstrated reduced elastin compared with wild-type 
mice, a finding corroborated on histology (Figure 4).93 
The ESMA MRI protocol has now been tested on anes-
thetized pigs, demonstrating good signal-to-noise ratio 
of the aortic wall and excellent colocalization of ESMA 
to elastin in electron microscopy. There are currently no 
studies using ESMA MRI in humans.
Aortic Microcalcification and 18F-Sodium 
Fluoride
Vascular medial microcalcification is the pathologi-
cal accumulation of hydroxyapatite crystals within the 
media of large arteries and has been strongly linked 
to adverse cardiovascular outcome. It occurs through 
multiple mechanisms that are separate from the intimal 
calcification that occurs in in atherosclerosis. Vascular 
medial microcalcification is understood to occur via 3 
primary mechanisms: calcium deposition on damaged 
elastin, excess intracellular calcium released by stressed 
smooth muscle cells into vesicles or through cell death, 
or pathological osteogenic phenotype switching by vas-
cular smooth muscle cells.95 Because the presence of 
medial microcalcification represents ongoing pathologi-
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could be a valuable marker of aortic wall disease. 
18F-sodium fluoride is a molecular tracer that binds to 
hydroxyapatite, thus allowing noninvasive detection 
and quantification of aortic wall microcalcification.96 
A recent study investigating the utility of 18F-sodium 
fluoride to predict clinical events in abdominal aortic 
aneurysms found that patients in the highest tertile of 
aneurysmal 18F-sodium fluoride uptake had the quick-
est growth rate and an increased incidence of surgical 
repair or rupture.97 Given the role that medial microcal-
cification plays in many common end points of patho-
logical change of ascending aortopathy (elastin calcifi-
cation, vascular smooth muscle apoptosis, extracellular 
matrix calcium deposition) and the promising results 
toward abdominal aortic aneurysms prognostication, it 
would appear to be an ideal candidate for translation in 
inherited thoracic aortopathy.
AORTIC INFLAMMATION AND 
18F-FLUORODEOXYGLUCOSE
Unlike abdominal aortic aneurysms, the inflammatory 
process in thoracic aortopathy is less pronounced, 
with only weak associations between immune system 
activation and thoracic aneurysm formation. Indeed, 
there is some association with T cell–mediated medial 
degeneration, but this appears to be a late manifes-
tation of the thoracic aneurysm formation process. 
18F-fluorodeoxyglucose is a positron emission tomog-
raphy radiotracer that nonspecifically highlights areas 
Figure 4. Emerging molecular imaging methods for identifying high-risk aortopathy.
Histological sections from a patient with Marfan syndrome who underwent elective aortic root replacement for dilated aorta highlighting known pathological end 
points in thoracic aortic disease (A and C) and corresponding examples of molecular imaging for each disease process (B and D). A, Elastin van Gieson staining 
demonstrating elastic fiber breaks (green arrows). B, Uptake of elastin-specific contrast agent was performed in control (wild-type [WT]) and FBN1C1039G/+ mice at 
the level of the ascending aorta with reduced uptake in the ascending aorta of FBN1c1039G/+ mice, suggesting lower elastin content and more elastin breaks. Adapt-
ed from Okamura et al.93 Copyright © 2014, American Heart Association, Inc. C, Picrosirius red staining for type I and III collagen with areas of reduced uptake in 
the media and adventitia (green and orange arrows). Collagen-rich (left, yellow arrow) and collagen-poor (right, yellow arrows) abdominal aortic aneurysms in 
an angiotensin II infusion/transforming growth factor-β neutralization mouse model. ESMA indicates elastin-specific magnetic resonance imaging contrast agent. 




 http://ahajournals.org by on M
ay 14, 2020









May 12, 2020 Circulation. 2020;141:1570–1587. DOI: 10.1161/CIRCULATIONAHA.119.0437561584
of high glucose metabolism, commonly found in ar-
eas with a high concentration of inflammatory cells or 
metabolically active cells. In abdominal aortic aneu-
rysms, high 18F-fluorodeoxyglucose positron emission 
tomography imaging has been linked to increased 
cardiovascular events in general, as well as correlating 
with increased inflammation and MMPs in abdomi-
nal aortic aneurysms.98 However, at present there are 
no studies directly assessing the relationship between 
18F-fluorodeoxyglucose uptake in the thoracic aorta 
and clinical outcomes focused on those with inherited 
aortopathy.
AORTIC DISEASE ACTIVITY AND 
NOVEL RADIOTRACERS
Although immune infiltration is not prevalent in inherit-
ed ascending aortopathy, vascular smooth muscle cells 
produce damaging MMPs under pathological condi-
tions that contribute to medial degeneration and aortic 
remodeling. In the angiotensin II model of abdominal 
aortic aneurysm, the MMP-specific radiotracer 99mTc-
RP805 correlated with aneurysm size and predicted rup-
ture or aneurysm formation.99 Although promising and 
relevant to ascending aortopathy, there are no reported 
applications in inherited thoracic aortopathy. Similar to 
MMP radiotracers, preclinical agents are being devel-
oped for visualizing collagen (Figure 4)94 and glycosami-
noglycans,100 which may have potential translation into 
thoracic aortic pathology, but translating these agents 
into human study will require significant work.
CONCLUSIONS
Inherited thoracic aortopathies encompass all patients 
born with an inherent risk of developing thoracic aor-
topathy. A combination of an abnormal hemodynamic 
profile and genetic abnormalities leading to aortic wall 
weakness predisposes these patients to life-threatening 
aortic dissection or rupture. Current management relies 
on aortic diameter, along with a few clinical risk factors, 
to decide on whether surgical intervention is required. 
However, there is international recognition that better 
models for predicting and preventing acute aortic events 
is required. Our understanding of the mechanisms un-
derpinning inherited aortopathies has improved sub-
stantially, although major uncertainties still surround 
the identification and management of some inherited 
aortopathies, particularly nsHTAD. Continuing to de-
velop large international collaborative research efforts is 
vital to improving management strategies for imaging, 
treatment, genetic screening, and counseling of these 
individuals. Novel therapies and biomarkers of thoracic 
aortopathies are urgently required. However, thus far, 
translating improved mechanistic understanding into re-
liable biomarkers or therapies has proved difficult.
TGFβ, MMPs, and TIMPs are all implicated in thoracic 
aortic wall disease. However, blood biomarker research 
has been hampered by variability in sampling and pro-
cessing methodology and their nonspecific nature. The 
molecule desmosine, on the other hand, appears to be 
a specific marker of elastin breakdown and warrants 
further attention.
Aortic diameter remains the primary indicator for 
surgery despite known issues with its sensitivity and 
specificity for predicting aortic events. Alternative im-
aging markers such as aortic stiffness may provide 
complementary information on aortic risk. Molecular 
imaging is a promising technique combining molecular 
biology with anatomic colocalization. Visualizing aor-
tic elastin and inflammation by ESMA and 18F-fluoro-
deoxyglucose positron emission tomography imaging, 
respectively, is an emerging technique for identifying 
high-risk inherited aortopathies that needs validation 
in human thoracic aortic aneurysms. Other radiotrac-
ers that target aortic wall collagen, microcalcification, 
MMPs, and glycosaminoglycans are at various stages of 
preclinical development and will be essential to improv-
ing our understanding of inherited aortopathies.
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